Report Overview

The Global Pompe disease drugs market size stood at USD 1.16 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Pompe disease is a genetic metabolic disorder that occurs in infants and is caused due to the mutations in the GAA gene responsible for producing the acid, alpha-glucosidase enzyme that converts glycogen into a simple form. The absence or mutation in the GAA gene leads to the accumulation of glycogen and results to have a heart problem, muscle weakness, liver damage that can lead to premature death in the new-born



Market Drivers

Increasing developments in the gene therapy and enzyme replacement therapies are the primary factors driving the growth of Pompe disease Market. However, inflated costs associated with the Pompe disease therapy could hinder the market growth opportunities. Moreover, research activities performed to find an effective treatment for the disease and the growth in the special regulatory drug designations for orphan drugs can further create the growth opportunities for Pompe disease market